Item | All (N = 285) | Group A (N = 165) | Group B (N = 89) | Group C (N = 31) | P |
---|---|---|---|---|---|
Age (y) | 44.5 ± 16.1 | 43.7 ± 16.0 | 45.3 ± 17.1 | 46.5 ± 13.3 | 0.456 |
Sex | Â | Â | Â | Â | 0.099 |
 Male | 188 (66.0%) | 117 (70.9%) | 54 (60.7%) | 17 (54.8%) |  |
 Female | 97 (34.0%) | 48 (29.1%) | 35 (39.3%) | 14 (45.2%) |  |
Ethnicity | Â | Â | Â | Â | 0.248 |
 Han Chinese | 277 (97.2%) | 160 (97.0%) | 88 (98.9%) | 29 (93.5%) |  |
 Others | 8 (2.8%) | 5 (3.0%) | 1 (1.1%) | 2 (6.5%) |  |
With concomitant disease | 142 (49.8%) | 82 (49.7%) | 47 (52.8%) | 13 (41.9%) | 0.580 |
Have concomitant medication | 127 (44.6%) | 7 (4.2%) | 89 (100.0%) | 31 (100.0%) |  < 0.001 |
Current diagnosis | Â | Â | Â | Â | 0.076 |
 POAG | 227 (79.6%) | 136 (82.4%) | 71 (79.8%) | 20 (64.5%) |  |
 OH | 58 (20.4%) | 29 (17.6%) | 18 (20.2%) | 11 (35.5%) |  |
Course of disease (days) |  |  |  |  |  < 0.001 |
 N (Nmiss) | 232 (53) | 154 (11) | 58 (31) | 20 (11) |  |
 Mean ± SD | 255.7 ± 786.6 | 101.6 ± 634.3 | 502.1 ± 733.8 | 728.1 ± 1433.7 |  |
Eye using the study drug | Â | Â | Â | Â | 0.221 |
 Right only | 21 (7.4%) | 8 (4.8%) | 10 (11.2%) | 3 (9.7%) |  |
 Left only | 11 (3.9%) | 7 (4.2%) | 2 (2.2%) | 2 (6.5%) |  |
 Both | 253 (88.8%) | 150 (90.9%) | 77 (86.5%) | 26 (83.9%) |  |
Target eye | Â | Â | Â | Â | Â |
 Right | 182 (63.9%) | 101 (61.2%) | 61 (68.5%) | 20 (64.5%) |  |
 Left | 103 (36.1%) | 64 (38.8%) | 28 (31.5%) | 11 (35.5%) |  |
Baseline IOP (mmHg) | 22.0 ± 4.2 | 22.4 ± 4.7 | 21.0 ± 3.5 | 22.5 ± 3.2 |  |